<p>根據 Envestnet Asset Management Inc.最近向證券交易委員會的提交文件，該公司在第三季度減少了對 Jazz Pharmaceuticals PLC（NASDAQ:JAZZ - 免費報告）9.5% 的持股。該公司在此期間出售了 10,744 股後，持有 102,181 股這家專業製藥公司的股票。Envestnet Asset Management Inc.在最近的報告期末持有 Jazz Pharmaceuticals 0.17% 的股份，價值 13,467,000 美元。</p>
<p>獲取 <strong>Jazz Pharmaceuticals</strong> 的提醒：</p>
<ul>
<li>Zymeworks 為長期投資者提供了希望</li>
</ul>
<p>其他一些對沖基金最近也增加或減少了對 JAZZ 的持股。LSV Asset Management 在第二季度將其在 Jazz Pharmaceuticals 的股份增加了 3.6%。LSV Asset Management 現在持有 2,553,742 股這家專業製藥公司的股票，價值 271,003,000 美元，此前在上個季度又收購了 87,576 股。Ameriprise Financial Inc.在第二季度將其在 Jazz Pharmaceuticals 的股份增加了 11.4%。Ameriprise Financial Inc.現在持有 1,867,399 股這家專業製藥公司的股票，價值 198,159,000 美元，此前在上個季度又購買了 191,637 股。摩根大通在第二季度將其在 Jazz Pharmaceuticals 的股份增加了 3.6%。摩根大通現在持有 1,721,294 股這家專業製藥公司的股票，價值 182,664,000 美元，此前在上個季度又收購了 59,252 股。Vestal Point Capital LP 在第二季度購買了 Jazz Pharmaceuticals 的新股份，價值約 127,344,000 美元。最後，Geode Capital Management LLC 在第二季度將其在 Jazz Pharmaceuticals 的股份增加了 1.5%。Geode Capital Management LLC 現在持有 1,171,755 股這家專業製藥公司的股票，價值 124,366,000 美元，此前在此期間又收購了 16,757 股。機構投資者和對沖基金持有該公司 89.14% 的股份。</p>
<h2>Jazz Pharmaceuticals 股票上漲 0.0%</h2>
<p>JAZZ 週二開盤價為 166.31 美元。該公司的債務與股本比率為 1.09，速動比率為 1.44，流動比率為 1.65。Jazz Pharmaceuticals PLC 的 52 周低點為 95.49 美元，52 周高點為 182.99 美元。該公司的 50 日移動平均線為 167.54 美元，200 日移動平均線為 147.79 美元。該股票的市值為 101 億美元，市盈率為-27.40，市盈增長比率為 0.89，貝塔值為 0.26。</p>
<h2>分析師評級上調與下調</h2>
<ul>
<li>頂級大麻股票：投資機會眾多（你並沒有錯過機會）</li>
</ul>
<p>幾家研究公司對 JAZZ 發佈了報告。Weiss Ratings 在 12 月 29 日的研究報告中重申了對 Jazz Pharmaceuticals 股票的 “賣出（d+）” 評級。美國銀行在 11 月 18 日的報告中將 Jazz Pharmaceuticals 的目標價從 230.00 美元上調至 247.00 美元，並給予該股票 “買入” 評級。Truist Financial 在 1 月 12 日的研究報告中將 Jazz Pharmaceuticals 的目標價從 220.00 美元上調至 230.00 美元，並給予該股票 “買入” 評級。Wall Street Zen 在 11 月 8 日的報告中將 Jazz Pharmaceuticals 的評級從 “持有” 上調至 “強力買入”。最後，富國銀行在 11 月 18 日的研究報告中將 Jazz Pharmaceuticals 的目標價從 170.00 美元上調至 235.00 美元，並給予該股票 “超配” 評級。十四位研究分析師對該股票給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，平均目標價為 205.67 美元。</p>
<p><strong>獲取我們對 JAZZ 的最新分析</strong></p>
<h2>Jazz Pharmaceuticals 的內部買賣</h2>
<p>在其他 Jazz Pharmaceuticals 的新聞中，董事 Bruce C. Cozadd 在 11 月 26 日的交易中出售了 77,500 股 Jazz Pharmaceuticals 的股票。這些股票以 177.81 美元的平均價格出售，總價值為 13,780,275.00 美元。交易完成後，該董事直接持有 393,332 股公司股票，價值 69,938,362.92 美元。這筆交易代表了其持股的 16.46% 的減少。該出售在向 SEC 的文件中披露，文件可在此鏈接查看。此外，SVP Mary Elizabeth Henderson 在 12 月 9 日的交易中出售了 2,238 股公司的股票。這些股票以 169.51 美元的平均價格出售，總交易額為 379,363.38 美元。交易完成後，該高級副總裁持有公司 19,508 股，價值約 3,306,801.08 美元。這筆交易代表了其持股的 10.29% 的減少。該出售的披露信息可在 SEC 文件中找到。在過去三個月中，內部人士出售了 87,813 股公司股票，價值 15,564,549 美元。公司內部人士持有公司 4.30% 的股份。</p>
<h2>Jazz Pharmaceuticals 公司簡介</h2>
<p>（免費報告）</p>
<p>Jazz Pharmaceuticals plc 是一家全球生物製藥公司，專注於開發和商業化神經科學和腫瘤學領域的療法。該公司的研發工作針對睡眠障礙、血液惡性腫瘤、罕見神經疾病和實體腫瘤等未滿足的醫療需求。Jazz 的產品組合包括用於治療嗜睡症、肝靜脈阻塞病、急性髓性白血病和其他嚴重疾病的療法。</p>
<p>Jazz Pharmaceuticals 的旗艦產品包括 Xyrem®（氧化鈉）和 Xywav®（鈣、鎂、鉀和氧化鈉），用於治療嗜睡症患者的肌肉無力和白天過度嗜睡。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票比爵士製藥更好</li>
<li>你的銀行賬户不再安全</li>
<li>英偉達首席執行官發出大膽的特斯拉呼籲</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>這隻 15 美元的股票可能會成為 2026 年的第一隻股票</li>
</ul>
<p><strong>想看看其他對爵士製藥持有股份的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取爵士製藥 PLC (NASDAQ:JAZZ - 免費報告) 的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFaWg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFaWg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在爵士製藥嗎？</h2>
<p>在考慮爵士製藥之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而爵士製藥並不在名單上。</p>
<p>雖然爵士製藥目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

標普生物技術 ETF - SPDR

醫療業 ETF - Vanguard

生物科技 ETF - VanEck Vectors

<p>Envestnet Asset Management Inc. 在第三季度減少了對爵士製藥的持股比例，下降了 9.5%，出售了 10,744 股。該公司目前持有 102,181 股，價值約為 1347 萬美元。其他對沖基金也調整了在爵士製藥的持倉。該股票開盤價為 166.31 美元，市值為 101 億美元。分析師的評級意見不一，普遍共識為 “適度買入”，平均目標價為 205.67 美元。最近的內部交易包括董事 Bruce C. Cozadd 出售了 77,500 股，交易金額約為 1378 萬美元</p>

<p>Envestnet Asset Management Inc. lessened its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 9.5% during the third quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The firm owned 102,181 shares of the specialty pharmaceutical company's stock after selling 10,744 shares during the period. Envestnet Asset Management Inc. owned 0.17% of Jazz Pharmaceuticals worth $13,467,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根據 Envestnet Asset Management Inc.最近向證券交易委員會的提交文件，該公司在第三季度減少了對 Jazz Pharmaceuticals PLC（NASDAQ:JAZZ - 免費報告）9.5% 的持股。該公司在此期間出售了 10,744 股後，持有 102,181 股這家專業製藥公司的股票。Envestnet Asset Management Inc.在最近的報告期末持有 Jazz Pharmaceuticals 0.17% 的股份，價值 13,467,000 美元。</p>
</div><p>Get <strong>Jazz Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Jazz Pharmaceuticals</strong> 的提醒：</p>
</div><ul>
<li>Zymeworks Offers Hope for More than Just Long-Term Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>Zymeworks 為長期投資者提供了希望</li>
</ul>
</div><p>A number of other hedge funds have also recently added to or reduced their stakes in JAZZ. LSV Asset Management increased its position in shares of Jazz Pharmaceuticals by 3.6% during the second quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company's stock worth $271,003,000 after acquiring an additional 87,576 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Jazz Pharmaceuticals by 11.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company's stock valued at $198,159,000 after purchasing an additional 191,637 shares during the last quarter. JPMorgan Chase &amp; Co. boosted its stake in Jazz Pharmaceuticals by 3.6% in the second quarter. JPMorgan Chase &amp; Co. now owns 1,721,294 shares of the specialty pharmaceutical company's stock valued at $182,664,000 after acquiring an additional 59,252 shares during the last quarter. Vestal Point Capital LP purchased a new position in Jazz Pharmaceuticals in the second quarter valued at approximately $127,344,000. Finally, Geode Capital Management LLC raised its stake in Jazz Pharmaceuticals by 1.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,171,755 shares of the specialty pharmaceutical company's stock valued at $124,366,000 after acquiring an additional 16,757 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.</p>
<div class="lb-trans"><p>其他一些對沖基金最近也增加或減少了對 JAZZ 的持股。LSV Asset Management 在第二季度將其在 Jazz Pharmaceuticals 的股份增加了 3.6%。LSV Asset Management 現在持有 2,553,742 股這家專業製藥公司的股票，價值 271,003,000 美元，此前在上個季度又收購了 87,576 股。Ameriprise Financial Inc.在第二季度將其在 Jazz Pharmaceuticals 的股份增加了 11.4%。Ameriprise Financial Inc.現在持有 1,867,399 股這家專業製藥公司的股票，價值 198,159,000 美元，此前在上個季度又購買了 191,637 股。摩根大通在第二季度將其在 Jazz Pharmaceuticals 的股份增加了 3.6%。摩根大通現在持有 1,721,294 股這家專業製藥公司的股票，價值 182,664,000 美元，此前在上個季度又收購了 59,252 股。Vestal Point Capital LP 在第二季度購買了 Jazz Pharmaceuticals 的新股份，價值約 127,344,000 美元。最後，Geode Capital Management LLC 在第二季度將其在 Jazz Pharmaceuticals 的股份增加了 1.5%。Geode Capital Management LLC 現在持有 1,171,755 股這家專業製藥公司的股票，價值 124,366,000 美元，此前在此期間又收購了 16,757 股。機構投資者和對沖基金持有該公司 89.14% 的股份。</p>
</div><h2>Jazz Pharmaceuticals Stock Up 0.0%</h2>
<div class="lb-trans"><h2>Jazz Pharmaceuticals 股票上漲 0.0%</h2>
</div><p>JAZZ opened at $166.31 on Tuesday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.44 and a current ratio of 1.65. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $182.99. The firm's fifty day moving average is $167.54 and its 200 day moving average is $147.79. The stock has a market cap of $10.10 billion, a price-to-earnings ratio of -27.40, a price-to-earnings-growth ratio of 0.89 and a beta of 0.26.</p>
<div class="lb-trans"><p>JAZZ 週二開盤價為 166.31 美元。該公司的債務與股本比率為 1.09，速動比率為 1.44，流動比率為 1.65。Jazz Pharmaceuticals PLC 的 52 周低點為 95.49 美元，52 周高點為 182.99 美元。該公司的 50 日移動平均線為 167.54 美元，200 日移動平均線為 147.79 美元。該股票的市值為 101 億美元，市盈率為-27.40，市盈增長比率為 0.89，貝塔值為 0.26。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><ul>
<li>Top Marijuana Stocks: Plenty of Investment Opportunities Abound (You're not Late to the Game)</li>
</ul>
<div class="lb-trans"><ul>
<li>頂級大麻股票：投資機會眾多（你並沒有錯過機會）</li>
</ul>
</div><p>Several research firms have issued reports on JAZZ. Weiss Ratings restated a &#34;sell (d+)&#34; rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 29th. Bank of America upped their price objective on Jazz Pharmaceuticals from $230.00 to $247.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, November 18th. Truist Financial lifted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, January 12th. Wall Street Zen upgraded shares of Jazz Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Saturday, November 8th. Finally, Wells Fargo &amp; Company upped their target price on shares of Jazz Pharmaceuticals from $170.00 to $235.00 and gave the stock an &#34;overweight&#34; rating in a research report on Tuesday, November 18th. Fourteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $205.67.</p>
<div class="lb-trans"><p>幾家研究公司對 JAZZ 發佈了報告。Weiss Ratings 在 12 月 29 日的研究報告中重申了對 Jazz Pharmaceuticals 股票的 “賣出（d+）” 評級。美國銀行在 11 月 18 日的報告中將 Jazz Pharmaceuticals 的目標價從 230.00 美元上調至 247.00 美元，並給予該股票 “買入” 評級。Truist Financial 在 1 月 12 日的研究報告中將 Jazz Pharmaceuticals 的目標價從 220.00 美元上調至 230.00 美元，並給予該股票 “買入” 評級。Wall Street Zen 在 11 月 8 日的報告中將 Jazz Pharmaceuticals 的評級從 “持有” 上調至 “強力買入”。最後，富國銀行在 11 月 18 日的研究報告中將 Jazz Pharmaceuticals 的目標價從 170.00 美元上調至 235.00 美元，並給予該股票 “超配” 評級。十四位研究分析師對該股票給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，平均目標價為 205.67 美元。</p>
</div><p><strong>Get Our Latest Analysis on JAZZ</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 JAZZ 的最新分析</strong></p>
</div><h2>Insider Buying and Selling at Jazz Pharmaceuticals</h2>
<div class="lb-trans"><h2>Jazz Pharmaceuticals 的內部買賣</h2>
</div><p>In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 77,500 shares of Jazz Pharmaceuticals stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $177.81, for a total value of $13,780,275.00. Following the completion of the transaction, the director directly owned 393,332 shares of the company's stock, valued at $69,938,362.92. This trade represents a 16.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of the business's stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $169.51, for a total transaction of $379,363.38. Following the completion of the sale, the senior vice president owned 19,508 shares in the company, valued at approximately $3,306,801.08. This trade represents a 10.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 87,813 shares of company stock worth $15,564,549. Company insiders own 4.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Jazz Pharmaceuticals 的新聞中，董事 Bruce C. Cozadd 在 11 月 26 日的交易中出售了 77,500 股 Jazz Pharmaceuticals 的股票。這些股票以 177.81 美元的平均價格出售，總價值為 13,780,275.00 美元。交易完成後，該董事直接持有 393,332 股公司股票，價值 69,938,362.92 美元。這筆交易代表了其持股的 16.46% 的減少。該出售在向 SEC 的文件中披露，文件可在此鏈接查看。此外，SVP Mary Elizabeth Henderson 在 12 月 9 日的交易中出售了 2,238 股公司的股票。這些股票以 169.51 美元的平均價格出售，總交易額為 379,363.38 美元。交易完成後，該高級副總裁持有公司 19,508 股，價值約 3,306,801.08 美元。這筆交易代表了其持股的 10.29% 的減少。該出售的披露信息可在 SEC 文件中找到。在過去三個月中，內部人士出售了 87,813 股公司股票，價值 15,564,549 美元。公司內部人士持有公司 4.30% 的股份。</p>
</div><h2>Jazz Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Jazz Pharmaceuticals 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.</p>
<div class="lb-trans"><p>Jazz Pharmaceuticals plc 是一家全球生物製藥公司，專注於開發和商業化神經科學和腫瘤學領域的療法。該公司的研發工作針對睡眠障礙、血液惡性腫瘤、罕見神經疾病和實體腫瘤等未滿足的醫療需求。Jazz 的產品組合包括用於治療嗜睡症、肝靜脈阻塞病、急性髓性白血病和其他嚴重疾病的療法。</p>
</div><p>Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.</p>
<div class="lb-trans"><p>Jazz Pharmaceuticals 的旗艦產品包括 Xyrem®（氧化鈉）和 Xywav®（鈣、鎂、鉀和氧化鈉），用於治療嗜睡症患者的肌肉無力和白天過度嗜睡。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Jazz Pharmaceuticals</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Nvidia CEO Issues Bold Tesla Call</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>This $15 Stock Could Go Down as the #1 Stock of 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比爵士製藥更好</li>
<li>你的銀行賬户不再安全</li>
<li>英偉達首席執行官發出大膽的特斯拉呼籲</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>這隻 15 美元的股票可能會成為 2026 年的第一隻股票</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JAZZ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對爵士製藥持有股份的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取爵士製藥 PLC (NASDAQ:JAZZ - 免費報告) 的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFaWg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=JAZZ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Jazz Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在爵士製藥嗎？</h2>
</div><p>Before you consider Jazz Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮爵士製藥之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而爵士製藥並不在名單上。</p>
</div><p>While Jazz Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然爵士製藥目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Envestnet Asset Management Inc. Sells 10,744 Shares of Jazz Pharmaceuticals PLC $JAZZ

Market Beat

動態生物技術與基因組 ETF - Invesco

紐交所高增長板生物技術指數 ETF - First Trust

爵士制藥

納斯達克生物科技指數 ETF - iShares Nasdaq

醫藥突破 ETF - ALPS

美國制藥 ETF - iShares

Invesco Nasdaq Biotechnology ETF

醫療業 ETF - SPDR

2 倍做多納斯達克生物技術 ETF - ProShares

Envestnet Asset Management Inc. 出售了 10,744 股爵士製藥 PLC 的股票 $JAZZ